Individualizing Selection of Hormonal Contraception
Abstract
Multiple hormonal contraception methods are available to prevent unintended pregnancies. The initial selection of a hormonal method includes consideration of contraception cost, frequency of use, failure rates, timing to return to fertility after discontinuation, and medical contraindications. The Centers for Disease Control and Prevention U.S. Medical Eligibility Criteria for Contraceptive Use provides an extensive, standard reference for reviewing contraindications for contraceptive use. Following the initial selection of the hormonal contraceptive, anticipating and managing adverse effects improves adherence and consequently, prevention of unintended pregnancy. Approaches to improve tolerability include reducing the hormone free interval, adjusting the estrogen and progestin doses, and switching to a different route of administration.
References
Healthy People 2020 Topics and Objectives: Family Planning Objective. < http://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=13 >; Accessed 27.10.13.
Finer LB, Zolana MR. Unintended pregnancy in the United States: incidence and disparities-2006. Contraception. 2011; 84(5): 478-485
Sonfield A, Kost K, Gold RB, Finer LP. The public costs of births resulting from unintended pregnancies: national and state-level estimates. Perspect Sex Reprod Health. 2011;43(2):94-102
Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404
Trussell J, Lalla AM, Doan QV, et al: Cost effectiveness of contraceptives in the United States. Contraception. 2009;79(1):5-14
Trussel J, Guthrie KA. Choosing a contraceptive: efficacy, safety, and personal considerations. In: Hatcher RA, Trussel J, Nelson AL, et al, eds. Contraceptive Technology, twentieth ed.,
Ardent Media, Inc., Atlanta, Georgia, Ardent Media, Inc., 2011.
Centers for Disease Control and Prevention. U.S. selected practice recommendations for contraceptive use, 2013 – adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, second edition. Morb Mortality Wkly Rep. 2013;62(5):1-60
ACOG Committee Opinion. No. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol . 2009;114(6):1434-8
Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2010 – adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4nd edition. Morb Mortality Wkly Rep. 2010;59:1-85
ACOG Committee Opinion. No. 505: Understanding and using the US medical eligibility criteria for contraceptive use, 2010. Obstet Gynecol. 2011;118(3):754-760
Stewart FH, Harper CC, Ellertson CE, et al: Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA. 2001;285:2232-2239
ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6): 1453-1472
Nelson AL, Cwiak C. Combined oral contraceptives (COCs). In: Hatcher RA, Trussel J, Nelson AL, et al, eds. Contraceptive Technology, twentieth ed., Ardent Media, Inc., Atlanta, Georgia, Ardent Media, Inc., 2011.
Mantha S, Karp R, Raghavan V, et al: Assessing the risk of venous thromboembolism in women taking progestin only contraception: a meta-analysis. BMJ. 2012;345(e4944)
Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76(4):267-72
Littlejohn KE. Hormonal contraceptive use and discontinuation because of dissatisfaction: differences by race and education. Demography. 2012;49(4):1433-52
Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74(2):1003
Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011;117(1):33-40
Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol. 2010;202(3):221-231
Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, et al: An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85(5):437-45
Edelman A, Gallo MF, Jensen JT, et al: Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Data Syst Rev. 2010;8:CD004695
Kaunitz AM, Portman DJ, Hait H, Reape KZ. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Contraception. 2009;79(5):350-5
Gallo MF, Nanda K, Grimes DA, et al: 20ug versus >20 ug estrogen combined oral contraceptives for contraception. Cochrane Data Syst Rev. 2013;8:CD003989
Fruzzetti F, Tremollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28(5):400-8
Klipping C, Duijkers I, Parke S, et al: Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11(2):159-70
Lawrie TA, Helmerhorst FM, Maitra NK, et al: Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Data Syst Rev. 2011;5:CD004861
Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Data Syst Rev. 2012;7:CD004425
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual symptoms. Cochrane Data Syst Rev. 2012;2:CD006586
Van Vliet HA, Grimes DA, Lopez LM, et al: Triphasic versus monophasic oral contraceptives for contraception. Cochrane Data Syst Rev. 2011;11:CD003553
Van Vliet HAAM, Grimes DA, Helmerhorst FM, et al: Biphasic versus triphasic oral contraceptives for contraception. Cochrane Data Syst Rev. 2011;6:CD003283
VanVliet HAAM, Raps M, Lopez LM, Helmerhorst FM. Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Data Syst Rev. 2011;12:CD009038
Lopez LM, Grimes DA, Gallo MF, et al: Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Data Syst Rev. 2013;4:CD003552
Nanda K. Contraceptive patch and vaginal contraceptive ring. In: Hatcher RA, Trussel J, Nelson AL, et al, eds. Contraceptive Technology, twentieth ed., Ardent Media, Inc., Atlanta, Georgia, Ardent Media, Inc., 2011.
Ortho Evra. [package insert]. Titusville, New Jersey: Janssen Pharmaceuticals; June 2013.
Skyla [package insert]. Wayne, N.J.:Bayer HealthCare Pharmaceuticals, Inc.; September 2013.
Mirena [package insert]. Wayne, N.J.:Bayer HealthCare Pharmaceuticals, Inc.; February 2013.
Nexplanon [package insert]. Whitehouse Station, N.J.: Merck & Co., Inc.; September 2013.
Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2006;80(2):113-8
Depo-Provera CI [package insert]. New York, N.Y.: Pharmacia & Upjohn Co., Division of Pfizer Inc.; July 2011.
Depo-subQ provera 104 [package insert]. New York, N.Y.: Pharmacia & Upjohn Co., Division of Pfizer Inc.; November 2010.
Lopez LM, Edelman A, Chen M, et al: Progestin-only contraceptives: effects on weight. Cochrane Data Syst Rev. 2013;7:CD008815
Bottcher B, Radenbach K, Wildt L, Hinney B. Hormonal contraception and depression: a survey of the present state of knowledge. Arch Gynecol Obstet. 2012;286:231-36
Bartz D, Goldberg AB. Injectable contraceptives. In: Hatcher RA, Trussel J, Nelson AL, et al, eds. Contraceptive Technology, twentieth ed., Ardent Media, Inc., Atlanta, Georgia, Ardent Media, Inc., 2011.
Keyes KM, Cheslack-Postava K, Westhoff C, et al: Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 2013 [published online ahead of print 2013 September 15]. http://aje.oxfordjournals.org/content/early/2013/09/15/aje.kwt188.long. Accessed October 6, 2013.
Downloads
Published
How to Cite
Issue
Section
License
Accepted 2014-06-25
Published 2014-07-07
